Amé, Shanti

A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML:GFM's “pick a winner” trial, with the impact of somatic mutations

Adès, L., Duployez, N., Guerci‐Bresler, A., Laribi, K., Peterlin, P., Vey, N., Thepot, S., Wickenhauser, S., Zerazhi, H., Stamatoullas, A., et al. (2022) · British Journal of Haematology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 21

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia

Balsat, M., Alcazer, V., Etienne, G., Huguet, F., Berger, M., Cayssials, E., Charbonnier, A., Escoffre-Barbe, M., Johnson-Ansah, H., Legros, L., et al. (2023) · Leukemia Research

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 5